Silva MF, Carrilho FJ, Paranaguá-Vezozzo DC, Campos LT, LS Nacif, Diniz MA, Farias AQ, Alves VAF, D’Alburquerque LAC, Ono SK

Language: English
References: 29
Page: 796-802
PDF size: 101.86 Kb.

ABSTRACT

Background and aims. Percutaneous ethanol injection (PEI) is a well-established therapeutic option in patients with cirrhosis and hepatocellular carcinoma (HCC). The modified-Response Evaluation Criteria in Solid Tumors (m-RECIST) are an important tool for the assessment of HCC response to therapy. The aim was to evaluate whether HCC response according to the m-RECIST criteria could be an effective predictor of long-term survival in Barcelona Clinic Liver Cancer (BCLC) stage 0 and A HCC patients undergoing PEI. Material and methods. 79 patients were followed-up for median time of 26.8 months. HCC diagnosis was based on the current guidelines of the American Association for Study of the Liver Diseases (AASLD) and European Association for Study of the Liver (EASL). Patient survival was calculated from the first PEI session to the end of the follow-up. Results. The 1-, 3-, and 5-year overall survival rates were 79, 48 and 37%, respectively. In the multivariate analysis, Child-Pugh-Turcotte (CPT) (p = 0.022) and the response to m-RECIST criteria (p = 0.016) were associated with patient survival. CPT A patients who achieved Complete Response (CR) 1 month after PEI presented a 5-year survival rate of 55%. By contrast, the worst scenario, the group with CPT B but without CR had a 5-year survival rate of 9%, while the group with either CPT A or CR as a survival predictor had a 5-year survival rate of 31%. In conclusion, in BCLC stage 0 and A HCC-patients, m-RECIST at 1 month and Child A may predict survival rates after PEI.

REFERENCES

1. Parkin DM. The global health burden of infection-associated cancer in the year 2002. Int J Cancer 2006; 118: 3030-44.

2. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010; 78: 7-10.

3. Kikuchi L, Chagas AL, Alencar RSSM, Paranaguá-Vezozzo DC, Carrilho FJ. Clinical and epidemiological aspects of hepatocellular carcinoma in Brazil. Antiviral Therapy 2013; 18: 445-9.

4. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Eng J Med 1996; 334: 693-700.

5. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-35.

6. EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43. Silva MF, et al. , 2014; 13 (6): 796-802 802

7. Llovet JM, Fuster J, Bruix J. Intention-to-Treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.

8. Marrero J, Fontana RJ, Barrat A, Askari F, Conjeevaram HS, Su GL, Lok AS. Prognosis of hepatocellular carcinoma: comparisons of 7 staging systems in an American cohort. Hepatology 2005; 41: 707-16.

9. Lencioni R. Loco-regional treatment for hepatocellular carcinoma. Hepatology 2010; 52: 762-73.

10. Cho YC, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology 2009; 49: 453-9.

11. Lencioni R, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, Frings H, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation with percutaneous ethanol injection. Radiology 2003; 228: 235-40.

12. Lin SM, Lin CJ, Lin CC, Hsu YW, Chen YC. Radiofrequency ablation improves prognosis compared with ethanol ablation for hepatocellular carcinoma up to 4 cm. Gastroenterology 2004; 127: 1714-23.

13. Shiina S, Teratani T, Obi S, Sato S, Tateischi R, Fujishima T, Ishikawa T, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129: 111-20.

14. Lin SM, Lin CJ, Hsu Cw, Chen YC. Randomized controlled trial comparing percutaneous percutaneous thermal ablation, and percutaneous acetic acid injection to treat hepatocellular carcinoma 3 cm or less. Gut 2005; 54: 1151-6.

15. Germani G, Pleguezuelo M, Gurusamy K, Meyer T, Isgrò G, Burroughs AK. Clinical outcomes of radiofrequency ablation, percutaneous alcohol and acetic injection for hepatocellular carcinoma: a meta-analysis. J Hepatol 2010; 52: 380-8.

16. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010; 30: 52-60.

17. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 1982; 5: 649-55.

18. Villa E, Moles A, Ferreti I, Buttafoco P, Grottola A, Del Buono M, De Santis M, et al. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors’ status in the tumor is the strongest prognostic factor for survival. Hepatology 2000; 32: 233-8.

19. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002; 35: 519-24.

20. Livraghi T, Bolondi L, Lazzaroni S, Marin G, Morabito A, Rapaccini GL, Salmi A, et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. Cancer 1992; 15: 925-9.

21. Lencioni R, Bartolozzi Z, Caramella D, Paolicchi A, Carrai M, Maltinti G, Capria A, et al. Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Cancer 1995; 76: 1737-46.

22. Khan KN, Yatsuhaschi H, Yamasaki K, Yamasaki M, Inoue O, Koga M, Yano M. Prospective analysis of risk factors for hepatocellular carcinoma following ethanol injection. J Hepatol 2000; 32: 269-78.

23. Hou TI, Huang JC, Wu PC, Chang FY, Lee SD. Comparison of percutaneous acetic acid injection and percutaneous ethanol injection for hepatocellular carcinoma in cirrhotic patients: a prospective study. Scand J Gastroenterol 2003; 7: 770-8.

24. Brunello F, Veltri A, Caruzzi P, Pagano E, Ciccone G, Moretto P, Sacchetto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 2008; 43: 727-35.

25. Kuang M, Lu MD, Xie XY, Xu HX, Xu ZF, Liu GJ, Yin XL, et al. Ethanol ablation of hepatocellular carcinoma up to 5 cm by using a multiprolonged injection needle with high-dose strategy. Radiology 2009; 253: 552-61.

26. Ohnishi K, Yoshioka H, Ito S, Fujiwara K. Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma. Hepatology 1998; 27: 67-72.

27. Sala M, Llovet JM, Vilana R, Bianchi L, Solé M, Ayuso C, Brú C, et al. Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology 2004; 40: 1352-60.

28. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008; 100: 698-711.

29. Kikuchi L, Menezes M, Chagas AL, Tani CM, Alencar RSM, Diniz MA, Alves VAF, et al. Percutaneous radiofrequency ablation for early hepatocellular carcinoma: Risk factors for survival. World J Gastroenterol 2014; 20: 1585-93.